Dyslipidemia - Pipeline Review, H2 2015

Dyslipidemia - Pipeline Review, H2 2015 is a new market research publication announced by Reportstack.This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report available @ Dyslipidemia - Pipeline Review, H2 2015

Scope

- The report provides a snapshot of the global therapeutic landscape of Dyslipidemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Dyslipidemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Dyslipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Dyslipidemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Dyslipidemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Dyslipidemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

Acasti Pharma Inc. 43 Allergan Plc 44 Alnylam Pharmaceuticals, Inc. 45 Amgen Inc. 46 Arbutus Biopharma Corporation 47 Arisaph Pharmaceuticals, Inc. 48 Astellas Pharma Inc. 49 AstraZeneca Plc 50 AtheroNova Inc. 51 BASF SE 52 BCWorld Pharm Co. Ltd. 53 Cadila Pharmaceuticals Ltd. 54 Cardax Pharmaceuticals, Inc. 55 Catabasis Pharmaceuticals, Inc. 56 Cerenis Therapeutics Holding SA 57 Chong Kun Dang Pharmaceutical Corp. 58 CJ HealthCare Corp. 59 Connexios Life Sciences Pvt. Ltd. 60 CymaBay Therapeutics, Inc. 61 Daewoong Pharmaceutical Co., Ltd. 62 Daiichi Sankyo Company, Limited 63 Debiopharm International S.A. 64 Eli Lilly and Company 65 Gemphire Therapeutics Inc. 66 Genfit SA 67 GlaxoSmithKline Plc 68 HanAll Biopharma Co., Ltd. 69 Hanmi Pharmaceuticals, Co. Ltd. 70 Huons Co., Ltd. 71 Hyundai Pharmaceutical Co., Ltd. 72 Innovent Biologics, Inc. 73 IPCA Laboratories Limited 74 Isis Pharmaceuticals, Inc. 75 Jeil Pharmaceutical Co., Ltd. 76 Jenrin Discovery, Inc. 77 JW Pharmaceutical Corporation 78 Kissei Pharmaceutical Co., Ltd. 79 Kotobuki Pharmaceutical Co., Ltd. 80 Kowa Company, Ltd. 81 Kymab Limited 82 LG Life Science LTD. 83 Lipicard Technologies Limited 84 Lotus Pharmaceutical Co., Ltd. 85 Merck & Co., Inc. 86 Nimbus Therapeutics, LLC 87 Nippon Chemiphar Co., Ltd. 88 Pfizer Inc. 89 Pharmena SA 90 Prometheon Pharma, LLC 91 Protalix BioTherapeutics, Inc. 92 Sancilio & Company, Inc. 93 Takeda Pharmaceutical Company Limited 94 Thetis Pharmaceuticals LLC 95 Torrent Pharmaceuticals Limited 96 Viking Therapeutics, Inc. 97 Yuhan Corporation 98

Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###